BB Biotech beats benchmark with USD NAV gains - SEB
5 augusti, 10:53
5 augusti, 10:53
BB Biotech reported a Q2 net loss of CHF?100m, primarily due to a ~10% depreciation in the USD/CHF exchange rate. Despite this, NAV rose 5.5% in USD, outperforming the Nasdaq Biotech Index by 1.5pp. The share price rose 10.5% in USD terms. From the beginning of 2025 to 1 August, the NAV discount narrowed from 15.0% to 10.9%.
SEB Research
This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.
5 augusti, 10:53
BB Biotech reported a Q2 net loss of CHF?100m, primarily due to a ~10% depreciation in the USD/CHF exchange rate. Despite this, NAV rose 5.5% in USD, outperforming the Nasdaq Biotech Index by 1.5pp. The share price rose 10.5% in USD terms. From the beginning of 2025 to 1 August, the NAV discount narrowed from 15.0% to 10.9%.
SEB Research
This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.
Fonder
Konjunktur
Novo Nordisk
Aktieråd
Analys
Fonder
Konjunktur
Novo Nordisk
Aktieråd
Analys
1 DAG %
Senast
OMX Stockholm 30
1 DAG %
Senast
2 566,53